Unable to display view head.php file not found.
 
 

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 18

Inclusion Criteria of RE-LY

The Figure shows the inclusion criteria for RE-LY.[108] Although these criteria did not exactly parallel the CHADS2 or CHA2DS2-VASc score criteria, there was significant congruence.  Of note is that low-dose daily aspirin was allowed for all these patients on anticoagulation therapy, although relatively few patients were on aspirin. In addition, patients were allowed to take antiplatelet clopidogrel, although only about 6% did so.

 Reiffel JA. Am J Med 2013; 126: 00-00.

Complete references for all slides

References

[108] Ezekowitz MD, Connolly S, Parekh A, et al.. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805-810.

Unable to display view foot.php file not found.